Contrave versus Wellbutrin for weight loss: shared bupropion is not equivalence
Contrave combines naltrexone and bupropion in a weight-management product. Wellbutrin contains bupropion but is labeled for depression and seasonal affective disorder. The overlap raises a medication-reconciliation question, not a substitution shortcut.
Contrave is not Wellbutrin under a weight-loss name. Contrave is an FDA-approved fixed extended-release product containing naltrexone plus bupropion for long-term excess-weight reduction and maintenance in its labeled adult population, alongside reduced-calorie eating and activity. Wellbutrin XL contains bupropion without naltrexone and has depression and seasonal-affective-disorder indications, not an FDA weight-management indication. Because both include bupropion, the Contrave label contraindicates taking it with another bupropion-containing product. A prescriber must review the complete medication list rather than treating one as a cheaper substitute for the other.12
Two product names, three distinct questions
The first question is what is in the product? The second is what use did FDA approve for that exact product? The third is what happens if someone already takes a related medicine? A search comparison that asks only which one “causes more weight loss” skips the information most likely to change a real visit.
| Feature | Contrave | Wellbutrin XL |
|---|---|---|
| Ingredients | Naltrexone plus bupropion, fixed extended-release product | Bupropion extended-release without naltrexone |
| Cited FDA-labeled purpose | Long-term excess-weight reduction and maintenance for specified adults | Major depressive disorder and seasonal affective disorder |
| Question if both names appear on a list | Current label contraindicates use with other bupropion products | Do not assume another bupropion prescription can simply be layered on |
| Evidence boundary | Data for its studied combination and population | Evidence for its own indications, not proof of an equivalent weight regimen |
The current Contrave label states its long-term indication. That does not mean the product is appropriate for every person seeking weight care or that Wellbutrin has suddenly gained the same indication. Likewise, evidence for a combination product does not prove that a bupropion tablet alone will reproduce its benefit or safety profile. A named combination has its own formulation, label, warnings and monitoring instructions.12
Why medication reconciliation comes before the weight discussion
Contrave’s label is explicit about use with another bupropion-containing product. A person taking Wellbutrin or another bupropion medicine should tell the prospective weight-management prescriber before receiving a new prescription. The label also warns about other conditions and medicines that require review, including opioid-related concerns because Contrave contains naltrexone. Those are reasons for a clinician to check the full list, not instructions to stop or adjust a medicine independently.1
The naltrexone component makes an existing opioid prescription or opioid-use-disorder treatment a separate reconciliation question, even if no bupropion is duplicated. Contrave’s label lists chronic opioid use and acute opioid withdrawal among its contraindications. A weight consultation should identify who manages that treatment or any planned pain care before proposing the combination. Switching to Wellbutrin does not answer whether the original mental-health indication remains covered, either; the current prescriber and proposed weight-care clinician need a coordinated plan.12
Bring all prescription and nonprescription products, including medicines from a mental-health clinician or telehealth service. A provider who sees only a weight-clinic intake form may miss a drug prescribed elsewhere. Ask how the weight-care practice coordinates with the clinician managing depression or another condition. A shift between treatments, if considered, is a separate supervised decision; there is no universal online cross-taper or ingredient-equivalence calculation.
If a program proposes separate naltrexone and bupropion prescriptions instead of the fixed Contrave product, ask the prescriber to identify the exact regimen and explain the evidence and regulatory status for that plan. It should not be advertised as the approved Contrave formulation merely because the ingredient names match.
What a useful comparison visit produces
A good visit ends with a written answer to four questions: what health goal is being treated, why the named product is being considered, what current medicines or conditions affect the plan, and when the outcome and tolerability will be reviewed. That applies to any prescription weight-management discussion. For Contrave versus Wellbutrin, the essential extra step is checking duplicate bupropion and distinguishing depression treatment from weight management.
The Contrave-versus-Qsymia guide compares two differently composed weight-management products. This page answers the narrower shared-bupropion and substitution question. Use Treomark’s medical weight-management provider discovery to find a practice that can review your entire medication list and provide a product-specific explanation rather than a brand-name shortcut.
Sources
- National Library of Medicine DailyMed. Contrave prescribing information, updated 2025. Fixed naltrexone/bupropion extended-release product, current weight-management indication and contraindication with other bupropion products. Accessed .
- National Library of Medicine DailyMed. Wellbutrin XL prescribing information. Bupropion-only extended-release product and depression/seasonal-affective-disorder indications, not a weight-management label. Accessed .